Cancer Cell

Papers
(The H4-Index of Cancer Cell is 104. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Accelerated approvals: Early-phase success or premature authorization?1570
Characterization of the generic mutant p53-rescue compounds in a broad range of assays776
KIT as a therapeutic target in neuroendocrine prostate cancer511
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas504
Diet-microbiome interactions in cancer472
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer396
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer374
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer364
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling353
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition338
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer324
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations317
Spatial profiling technologies illuminate the tumor microenvironment316
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton314
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients293
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron290
High endothelial venules in cancer: Regulation, function, and therapeutic implication277
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer266
T cell dynamism and immune-related adverse events266
B cell heterogeneity in cancer comes of age261
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation261
Bacteria in metastatic sites: Unveiling hidden players in cancer progression259
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer255
The aging lung microenvironment awakens melanoma metastases250
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma243
A holistic view of cancer234
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors233
Challenges in neoantigen-directed therapeutics232
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer228
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity227
Cancer vaccines224
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses218
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer216
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer213
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer209
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion208
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin206
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments206
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics204
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma204
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer203
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients203
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma191
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population186
Challenges and opportunities for modeling aging and cancer186
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma185
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma184
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation182
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade181
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells177
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts177
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding177
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors175
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma174
Immunosensitivity cuts across mismatch repair status in colorectal cancer174
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?173
A genetic portrait of metastatic seeds in lung adenocarcinoma170
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation169
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity169
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy168
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver167
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification166
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis162
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer161
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy158
Dissecting bulk transcriptomes of diffuse large B cell lymphoma145
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade144
ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy139
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers138
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis137
Integrated proteogenomic characterization of glioblastoma evolution137
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1136
Tumor-infiltrating lymphocytes: A new hope135
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma133
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions132
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies132
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD130
A path to translation: How 3D patient tumor avatars enable next generation precision oncology130
Immune determinants of the pre-metastatic niche129
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment128
Midkine as a driver of age-related changes and increase in mammary tumorigenesis127
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring127
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells126
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma125
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells124
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes121
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness120
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study118
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers116
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells116
Multiplex computational pathology for treatment response prediction115
Tumors on different wavelengths114
GDF15 research from bench to bedside112
Firing up neutrophil anti-tumor immunity with cocktails111
The winner takes it all: Competition drives clonal selection in gliomagenesis111
A circular RNA in neuroendocrine carcinomas110
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy109
New horizons at the interface of artificial intelligence and translational cancer research108
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial108
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma108
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance107
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma107
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations106
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment105
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer104
0.10385394096375